Key Insights

Highlights

Success Rate

84% trial completion

Published Results

89 trials with published results (19%)

Research Maturity

255 completed trials (55% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.6%

49 terminated out of 461 trials

Success Rate

83.9%

-2.6% vs benchmark

Late-Stage Pipeline

8%

39 trials in Phase 3/4

Results Transparency

35%

89 of 255 completed with results

Key Signals

89 with results84% success49 terminated

Data Visualizations

Phase Distribution

371Total
Not Applicable (70)
Early P 1 (6)
P 1 (96)
P 2 (160)
P 3 (28)
P 4 (11)

Trial Status

Completed255
Recruiting59
Terminated49
Unknown48
Active Not Recruiting26
Withdrawn14

Trial Success Rate

83.9%

Benchmark: 86.5%

Based on 255 completed trials

Clinical Trials (461)

Showing 20 of 20 trials
NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT04659343RecruitingPrimary

TDM for Optimized Outcome in Patients With mRCC.

NCT03977571Not ApplicableRecruitingPrimary

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

NCT05946993Not ApplicableActive Not Recruiting

Linking In With Advice and Supports for Men Impacted by Metastatic Cancer

NCT00026884Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT05520099Active Not Recruiting

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

NCT03354390Phase 1Active Not RecruitingPrimary

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

NCT04393350Phase 2Active Not RecruitingPrimary

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

NCT00050752Recruiting

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

NCT00033137Recruiting

Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

NCT05861947Phase 1Terminated

A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

NCT00814021Phase 2CompletedPrimary

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

NCT06525831Not ApplicableRecruitingPrimary

Rein 3D PRINT MECHANICS

NCT05969496Phase 2Recruiting

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

NCT06362369Phase 1Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT07401875Phase 1Recruiting

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

NCT02964078Phase 2CompletedPrimary

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

NCT06532422RecruitingPrimary

Study of Post-operative Complications After Laparoscopic Outpatient Nephrectomy

NCT00001238RecruitingPrimary

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

NCT03786796Phase 2Recruiting

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

Scroll to load more

Research Network

Activity Timeline